At present, BRIP1 germline modifications are not clearly associated with an increased risk for breast cancer; conversely, there is a strong association with ovarian cancer with an absolute lifetime risk up to 15% and risk-reducing surgery is recommended at 45–50 years of age [42]. Here, BRIP1 is linked to ovarian carcinoma.